BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a
biotechnology company developing targeted, safe treatments for cancer, today
announced multiple updates including completion of its development of a novel
frozen formulation of Bria-IMT, its upcoming attendance at the Biotech Showcase
taking place Jan. 7-9, 2019 in San Francisco, and the acceptance of an abstract
for presentation of advances in Bria-IMT and BriaDX programs at the 2019
Keystone Symposia scientific conference taking place Jan. 20-24, 2019, in
Vancouver, British Columbia. According to the update, the new frozen Bria-IMT
formulation will provide for on-demand shipment to clinical sites and
accommodate higher volumes of patients at reduced costs per-dose.
“Currently, the old formulation of Bria-IMT used in the
clinical trials was cumbersome to prepare, as it had to be processed the day
before administration to patients,” BriaCell President and CEO Dr. Bill
Williams stated in the news release. “This created a great deal of
inconvenience and complexities for the manufacturer, clinicians and patients.
The new frozen formulation has shown improved potency and stability in vitro
and, based on its constituents and injection route, is expected to be highly
bioavailable. This enhances Bria-IMT’s potential to address patient needs as a
ready-to-use treatment alternative that can be prepared in advance, is easily
transportable to distant locations in large quantities, is easy to use, and is
safe and highly effective. We are excited to add this novel technology to our
growing immunotherapy franchise as we advance safe and effective treatment
solutions for advanced breast cancer, an unmet medical need. We look forward to
the efficacy data of our ongoing clinical trial, which will provide further
evidence for this promising novel therapy to bring hope to patients with
advanced breast cancer.”
To view the full press release, visit http://ibn.fm/jFjMS
About BriaCell
BriaCell is an immuno-oncology focused biotechnology company
developing targeted and safe approaches for the management of cancer. BriaCell
is currently conducting a Phase I/IIa clinical trial of Bria-IMT, its lead
candidate, in a combination study with pembrolizumab [Keytruda; manufactured by
Merck & Co., Inc.] or ipilimumab [Yervoy; manufactured by Bristol-Myers
Squibb Company]. The combination study is listed in ClinicalTrials.gov as
NCT03328026. BriaCell is developing Bria-OTS, an off-the-shelf personalized
immunotherapy, for advanced breast cancer. Bria-OTS immunotherapy treatments
are personalized to match the patient without the need for personalized
manufacturing. Bria-OTS, which is expected to cover over 90 percent of the
patient population, is designed to produce a potent and selective immune response
against the cancer of each patient while eliminating the time, expense, and
complex manufacturing logistics associated with other personalized
immunotherapies. For more information, visit the company’s website at www.BriaCell.com.
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment